Profiel
Neil M.
Frazer is the founder of DMK Pharmaceuticals Corp.
(Old).
He worked as a Chief Medical Officer at Chimerix, Inc. and OncoSil Medical Ltd.
He also served as a Non-Executive Director & Chief Medical Officer at Immutep Ltd.
Mr. Frazer completed his undergraduate degree at The University of Edinburgh.
Eerdere bekende functies van Neil M. Frazer
| Bedrijven | Functie | Einde |
|---|---|---|
| ONCOSIL MEDICAL LIMITED | Algemeen Directeur | 09-09-2014 |
DMK Pharmaceuticals Corp. (Old)
 DMK Pharmaceuticals Corp. (Old) BiotechnologyHealth Technology DMK Pharmaceuticals Corp. (Old) was an American commercial stage neuro-biotech company that focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. The company's approved products included Zimhi® (naloxone) injection for the treatment of opioid overdose and Symjepi® (epinephrine) injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company was founded by Neil M. Frazer and Ebrahim Versi. DMK Pharmaceuticals Corp. was acquired by DMK Pharmaceuticals Corp. on May 25, 2023 for $27 million. | Oprichter | - |
| IMMUTEP LIMITED | Hoofd Techniek/Wetenschap/O&O | - |
| CHIMERIX, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Neil M. Frazer
| The University of Edinburgh | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| IMMUTEP LIMITED | Health Technology |
| ONCOSIL MEDICAL LIMITED | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
DMK Pharmaceuticals Corp. (Old)
DMK Pharmaceuticals Corp. (Old) BiotechnologyHealth Technology DMK Pharmaceuticals Corp. (Old) was an American commercial stage neuro-biotech company that focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. The company's approved products included Zimhi® (naloxone) injection for the treatment of opioid overdose and Symjepi® (epinephrine) injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company was founded by Neil M. Frazer and Ebrahim Versi. DMK Pharmaceuticals Corp. was acquired by DMK Pharmaceuticals Corp. on May 25, 2023 for $27 million. | Health Technology |